Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This treatment eliminates the need for one to six weeks of daily external beam radiation therapy,allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020,GammaTile has been offered in more than 95 hospitals, with more centers being added each month. For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn. Media Contacts: Lori KaganGT Medical Technologies lkagan@gtmedtech.com Dawn FallonNew Dawn Communications dfallon@newdawncomms.com SOURCE GT Medical Technologies